A- A A+

The Chinese version of obsessive compulsive drug use scale: validation in outpatient methadone maintenance treatment program. 

Gong H, Zhang Y, Ren Q, Zhou Z, Zhou H, Sun X, Zhang C, Voon V, Zhao M, Yu S. 

BMC Psychiatry. 2020 Sep 25;20(1):465. doi: 10.1186/s12888-020-02843-2. PMID: 32977774; PMCID: PMC7517618.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517618/

The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder - 2020 Focused Update

The ASAM National Practice Guideline 2020 focused update is intended to inform and empower clinicians, health system administrators, criminal justice system administrators, and policymakers who are interested in implementing evidence-based practices to improve outcomes for individuals with OUD. This is especially critical in the context of the ongoing COVID-19 emergency, which threatens to curtail patient access to evidence-based treatment.  

The document is an update to the previous NPG released in 2015 and includes major revisions to 35 existing recommendations, along with the addition of 13 new recommendations.

This focused update was developed over the course of 14 months with consensus from an independent committee of experts and the use of a rigorous RAND/RAM methodology facilitated by researchers from Research Triangle Institute (RTI).

https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf

EMCDDA operating guidelines for the risk assessment of new psychoactive substances

Summary

The purpose of these guidelines is to ensure compliance with the scope and requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) in respect to the risk assessment procedure for and reporting on new psychoactive substances.

To operationalise the technical aspects of the risk assessment, the guidelines are supported by a set of Guidance notes developed by the EMCDDA. The Guidance notes will be adapted as required in order to reflect developments in the field of new psychoactive substances and risk assessment. (EMCDDA, Lissabon, Dezember 2020)

https://www.emcdda.europa.eu/system/files/publications/13482/Risk%20Assessment%20guidelines.pdf

Schottland. Standards for Scotland: Access - Choice – Support -- Consultation on the standards&implementation

Medication Assisted Treatment (MAT), Schottland, November 2020

https://drugdeathstaskforce.scot/media/1164/sddt-mat-standards_for-consultation_nov2020.pdf

Prevention and Treatment of HIV Among People Living with Substance Use and/or Mental Disorders

This guide reviews interventions for people living with substance use and mental disorders who are at risk for or living with HIV. Selected interventions are in alignment with goals of the federal “Ending the HIV Epidemic: A Plan for America” (EHE) initiative.

SAMHSA – Substance Abuse and Mental Health Services Administration, Rockville, USA

Publication ID PEP20-06-03-001, Publication Date November 2020

https://store.samhsa.gov/product/Prevention-and-Treatment-of-HIV-Among-People-Living-with-Substance-Use-and-or-Mental-Disorders/PEP20-06-03-001

Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians. 

Abraham GM, Obley AJ, Humphrey LL, Qaseem A. World 

Ann Intern Med. 2020 Oct 6. doi: 10.7326/M19-3860. Epub ahead of print. PMID: 33017566.

https://www.acpjournals.org/doi/10.7326/M19-3860

Effects of the new prescribing standards in British Columbia on consumption of opioids and benzodiazepines and z drugs. 

Crabtree A, Rose C, Chong M, Smolina K. 

Can Fam Physician. 2019;65(5):e231-e237.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516682/

Changing Outdated Methadone Regulations That Harm Pregnant Patients 

McCarthy JJ, Jones HE, Terplan M, Rudolf VP, von Klimo MC. 

[published online ahead of print, 2020 Aug 18]. J Addict Med. 2020;10.1097/ADM.0000000000000720. doi:10.1097/ADM.0000000000000720

Abstract

https://pubmed.ncbi.nlm.nih.gov/32826620/

EMCDDA/ECDC. Call for expressions of interest: Phase 1 of collection of models of good practice - Joint ECDC/EMCDDA PWID Guidance (2011) update
The joint ECDC & EMCDDA guidance on Prevention and control of infectious diseases among people who inject drugs (2011) is currently being updated. In addition to ongoing systematic reviews of peer-reviewed literature, a collection of models of good practice has been initiated by the two agencies, that should add practice-based evidence derived from interventions implemented in real-life, European settings.
We are inviting applications to report models of good practice targeting PWID population. (ECDC- European Centre for Disease Prevention and Control, August 2020)

https://ec.europa.eu/eusurvey/runner/Models_PWID2020

Kanada. Federal prosecutors told to avoid drug possession charges when possible in new directive

Charges should be sought only in 'most serious cases,' says director of public prosecutions. (CBC, Kanada, 19.08.2020)

https://www.cbc.ca/news/politics/simple-drug-possession-change-1.5657423

USA. Treatment of Stimulant Use Disorders

This guide supports health care providers, systems, and communities seeking to treat stimulant use disorders. It describes relevant research findings, examines best practices, identifies knowledge gaps and implementation challenges, and offers useful resources. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, Juni 2020)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-06-01-001_508.pdf

Schweiz. Medizinische Empfehlungen für Opioidagonistentherapie (OAT) bei Opioidabhängigkeits-Syndrom 2020 

Erstellt durch Mitglieder der Schweizerischen Gesellschaft für Suchtmedizin, SSAM 

Verfalldatum: Januar 2025 

https://www.ssam.ch/cmf/site/assets/files/1102/28_04_2020_medizinische_empfehlungen_fur_opioidagonistentherapie_oat_bei_opioidabhangigkeits-syndrom_2020.pdf

UNODC – WHO. International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing. 

Geneva: World Health Organization and United Nations Office on Drugs and Crime; 2020. License: CC BY-NC-SA 3.0 IGO

https://www.unodc.org/documents/drug-prevention-and-treatment/UNODC-WHO_International_Standards_Treatment_Drug_Use_Disorders_April_2020.pdf

Canadian Guidelines on Opioid Use Disorder Among Older Adults.

Rieb LM, Samaan Z, Furlan AD, Rabheru K, Feldman S, Hung L, Budd G, Coleman D.

Can Geriatr J. 2020 Mar 30;23(1):123-134. doi: 10.5770/cgj.23.420. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067148/

Irland. Clinical guidelines for opioid substitute treatment. Guidance document for OST in the hospital setting (PDF) 

Appropriate policies and standard operating procedures for the provision of in-patient Opioid Substitution Treatment (OST) is paramount to patient safety when treating a person with an opioid dependency (prescribed or unprescribed). (Health Service Executive, Irland, 2020)

https://www.drugsandalcohol.ie/31766/1/ost-hospital-inpatient-summaryv7.pdf

USA. National Practice Guideline for the treatment of opioid use disorder

This Practice Guideline was developed for the treatment of opioid use disorder and the prevention of opioid overdose-related death

ASAM - American Society of Addiction Medicine, März 2020

https://www.asam.org/Quality-Science/quality/2020-national-practice-guideline

USA. Opioid Use Disorder: Treatment Guidelines for Nonspecialists

To expand access to treatment for OUD, the Substance Use Guideline Committee of the New York State Department of Health AIDS Institute (NYSDOH AI) has just published the Treatment of Opioid Use Disorder guideline, designed for use by primary care and other clinicians who don't specialize in the management of substance use disorders. The guideline is applicable in clinical care of OUD in primary care practice not only in New York but throughout the United States. (NEW YORK STATE DEPARTMENT OF HEALTH AIDS INSTITUTE, August 2019)

https://www.hivguidelines.org/substance-use/oud/

Schweiz. Genuss, Suchtmittelkonsum und Abhängigkeiten in Alterszentren

Musterkonzept «Genuss, Suchtmittelkonsum und Abhängigkeiten in Alterszentren»: Wie gelingt die Früherkennung und die Betreuung von Suchtbetroffenen im Pflegealltag? Dieses Musterkonzept (pdf, 28S.) zeigt praktische Herangehensweisen auf und dient Institutionen und Mitarbeitenden aus dem Pflegebereich als Grundlage für die Entwicklung eigener Lösungen. Es wurde vom Fachverband Sucht in Zusammenarbeit mit Infodrog, dem Gustav Benz Haus sowie weiteren Expertinnen und Experten aus der Alterspflege und der Suchthilfe entwickelt. (30.04.2019)

https://www.alterundsucht.ch/files/content/pdf-de/fs_konzept-suchtmittelkonsum-in-alterszentren.pdf

Drug-Induced Liver Injury EASL Guideline

Idiosyncratic (unpredictable) Drug-Induced Liver Injury is one of the most challenging liver disorders faced by hepatologists. This happens because of the myriad of drugs used in clinical practice. Also due to the available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers.  Therefore, this makes the diagnosis of Drug-Induced Liver Injury an uncertain process. One that requires a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe. It can lead to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed.
This Clinical Practice Guideline summarizes the available evidence on risk factors, diagnosis, management, risk minimization strategies for Drug-Induced Liver Injury. (EASL - The European Association for the Study of the Liver, April 2019) 

https://easl.eu/publication/cpg-drug-induced-liver-injury

ACP issues guideline for testosterone treatment in adult men with age-related low testosterone

ACP’s recommendations include treating for sexual dysfunction only, discontinuing treatment if sexual function does not improve, and not initiating treatment for other reasons

Philadelphia, January 7, 2020 – Physicians should prescribe testosterone for men with age-related low testosterone only to treat sexual dysfunction, the American College of Physicians (ACP) says in a new evidence-based clinical practice guideline published today in Annals of Internal Medicine. (American College of Physicians (ACP), 07.01.2020)

https://www.acponline.org/acp-newsroom/acp-issues-guideline-for-testosterone-treatment-in-adult-men-with-age-related-low-testosterone

Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians.

Qaseem A, Horwitch CA, Vijan S, et al, for the Clinical Guidelines Committee of the American College of Physicians. 

Ann Intern Med. 2020;172:126–133. [Epub ahead of print 7 January 2020]. doi.org/10.7326/M19-0882

https://annals.org/aim/fullarticle/2758507/testosterone-treatment-adult-men-age-related-low-testosterone-clinical-guideline

Kanada. Release of First-Ever National Clinical Guidelines on Substance Use Disorders among Older Canadians!

Toronto, Ontario – Canadian healthcare providers now have the tools they need to better support the prevention, assessment and treatment of older adults at risk of, or living with, substance use disorders. The Canadian Coalition for Seniors’ Mental Health (CCSMH) officially launched 4 sets of Clinical Guidelines on Substance Use Disorders in Older Adults today. (Canadian Coalition for Seniors' Mental Health, 20.01.2020)

https://ccsmh.ca/wp-content/uploads/2020/01/CCSMH-SUD-guidelines-Press-release-FINAL.pdf

Canadian Guidelines on Opioid Use Disorder Among Older Adults. 

Canadian Coalition for Seniors’ Mental Health, Toronto, Canada (2019)

According to the World Health Organization, people over the age of 50 accounted for 39% of deaths from drug use disorders in 2015. Of those deaths in older adults (age ≥ 65), approximately 75% were linked to the use of opioids (Degenhardt & Hall, 2012; UNODC, 2018). 

In Canada, 43.9% of adults > 55 years of age have used a prescription opioid and 1.1% of that group have done so daily (or almost daily) in the last year (Canadian Centre on Substance Use and Addiction, 2018).

There is a growing population of older adults developing opioid use disorder (OUD). In addition to this, there are older adults with longstanding OUD (including people who use illicit opioids) that require treatment for their addiction and related health problems.

https://ccsmh.ca/wp-content/uploads/2019/11/Canadian_Guidelines_Opioid_Use_Disorder_ENG.pdf

Opioid-Agonisten-Therapien - Leitprinzipien für Gesetzgebung und Reglementierung

Expertengruppe bezüglich gesetzlicher Rahmenbedingungen für die Behandlung des Opioidabhängigkeitssyndroms durch Verschreibung von Opioid-Agonisten-Arzneimittel

Pompidou Group/Groupe Pompidou, Council of Europe/Conseil de Europe, 2019

https://www.bag.admin.ch/dam/bag/de/dokumente/npp/drogen/sucht/hegebe/leitprinzipien-opioid-agonisten-therapien.pdf.download.pdf/GuidingPrinciples_GER__2019_%20190619.pdf

Opioid agonist treatment - Guiding principles for legislation and regulations

Expert group on the regulatory framework for the treatment of opioid dependence syndrome and the prescription of opioid agonist medicines.

Pompidou Group/Groupe Pompidou, Council of Europe/Conseil de Europe, 2019

https://rm.coe.int/2017-ppg-15-oat-guidingprinciples-final-eng/16808b6d9e

International Standards for the Treatment of Drug Use Disorders

WHO/UNODC, 2017

https://www.who.int/substance_abuse/activities/msb_treatment_standards.pdf

Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Feld JJ, Gordon SC, Heller T, Jhaveri RR, Jonas MM, Kiser JJ, Linas BP, Lo Re V, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Spradling P, Terrault NA, Trooskin SB, Verna EC, Wong JB, Woolley AE, Workowski KA.

Hepatology. 2019 Dec 9. doi: 10.1002/hep.31060. 

https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.31060

USA. Recovery Housing: Best practices and suggested guidelines.

(…) The SUPPORT legislation seeks to improve resident care for individuals suffering from a substance use disorder who are in need of supportive recovery-oriented transitional housing. The Administration has dedicated time, attention, and resources to ensuring that individuals with substance use disorders have access to lifesaving medications, treatments, and services in settings throughout the continuum of care, including recovery housing. This document is intended to serve as a guidance tool for states, governing bodies, treatment providers, recovery house operators, and other interested stakeholders to improve the health of their citizens related to substance use issues. This report identifies ten specific areas, or guiding principles, that will assist states and federal policy makers in defining and understanding what comprises safe, effective, and legal recovery housing. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, OKTOBER 2019)

https://www.samhsa.gov/sites/default/files/housing-best-practices-100819.pdf

Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury — United States, October 2019.

Siegel DA, Jatlaoui TC, Koumans EH, et al. 

MMWR Morb Mortal Wkly Rep. ePub: 11 October 2019. doi.org/10.15585/mmwr.mm6841e3

https://www.cdc.gov/mmwr/volumes/68/wr/mm6841e3.htm